• Immutep has completed the single ascending dose (SAD) portion of its IMP761 study
• IMP761 was well tolerated across all dose levels
• IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026

Immutep Limited, a clinical-stage biotechnology company targeting cancer and autoimmune diseases, has announced positive updates from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761, a first-in-class LAG-3 agonist antibody. The Company reported that the single ascending dose (SAD) portion of the study has been successfully completed, with dosing up to 14 mg/kg. IMP761 was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed to date. The study is currently progressing in the multiple ascending dose (MAD) portion, which is evaluating pharmacokinetics and safety across two dose levels. Completion of the MAD portion is expected in the third quarter of 2026. IMP761 continues to show a clear immunosuppressive effect in healthy participants challenged with a foreign antigen in an intra-dermal reaction, with durable inhibition of T-cell-mediated responses after a single administration. These first-in-human findings support the mechanistic aim of selectively silencing pathogenic, self-antigen-specific memory T cells via LAG-3 agonism and provide the basis for dose levels to be tested in a future phase II trial in patients with autoimmunity. IMP761 data, including Phase I results, will be presented at the European Alliance of Associations for Rheumatology (EULAR) annual congress in London, UK on 4th June 2026.

IMP761, a first-in-class immunosuppressive lymphocyte-activation gene-3 (LAG-3) agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the immune system.